PE00642009A1 - ribonucleic acid double strand to inhibit expression of the human E6AP gene and pharmaceutical composition comprising - Google Patents

ribonucleic acid double strand to inhibit expression of the human E6AP gene and pharmaceutical composition comprising

Info

Publication number
PE00642009A1
PE00642009A1 PE0005312008A PE0005312008A PE00642009A1 PE 00642009 A1 PE00642009 A1 PE 00642009A1 PE 0005312008 A PE0005312008 A PE 0005312008A PE 0005312008 A PE0005312008 A PE 0005312008A PE 00642009 A1 PE00642009 A1 PE 00642009A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
ribonucleic acid
double strand
inhibit expression
acid double
Prior art date
Application number
PE0005312008A
Other languages
Spanish (es)
Inventor
John Benson
Kevin Fitzgerald
Birgit Bramlage
Pamela Tan
Hans-Peter Vornlocher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US90809807P priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE00642009A1 publication Critical patent/PE00642009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Abstract

SE REFIERE A UN ARN DE DOBLE CADENA, EL CUAL COMPRENDE a)UNA PRIMERA SECUENCIA EN SENTIDO SELECCIONADA DE GUGAUAGCUCACAGGGAGATT, CUCAGCUUACCUUGAGAACTT, GAGGUUUUCAUAUGGUGACTT, ENTRE OTROS; INVOLVES A dsRNA, which comprises a) a first sequence SENSE IN SELECTED GUGAUAGCUCACAGGGAGATT, CUCAGCUUACCUUGAGAACTT, GAGGUUUUCAUAUGGUGACTT, among others; b)UNA SECUENCIA ANTISENTIDO CON UNA REGION DE COMPLEMENTARIEDAD DE MENOS DE 30 NUCLEOTIDOS DE LONGITUD, SELECCIONADA DE CUUCCCUGUGAGCUAUCACTT, GUUCUCAAGGUAAGCUGAGTT, GUCACCAUAUGAAAACCUCTT, ENTRE OTROS. b) an antisense sequence with a region of complementarity LESS THAN 30 nucleotides in length, SELECTED CUUCCCUGUGAGCUAUCACTT, GUUCUCAAGGUAAGCUGAGTT, GUCACCAUAUGAAAACCUCTT, among others. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA QUE COMPRENDE CUANDO MENOS DOS ARNds. ALSO it REFERS TO A METHOD FOR PREPARING AND PHARMACEUTICAL COMPOSITION at least two dsRNA. DICHO ARNds INHIBE LA EXPRESION DEL GEN E6AP POR CUANDO MENOS EL 40 POR CIENTO Y ES UTIL EN LA PREVENCION O TRATAMIENTO DE INFECCION POR VIRUS PAPILOMA HUMANO DsRNA inhibits expression SAID GENE E6AP BY AT LEAST 40 percent and is useful in the prevention or treatment of human papilloma virus INFECTION
PE0005312008A 2007-03-26 2008-03-24 ribonucleic acid double strand to inhibit expression of the human E6AP gene and pharmaceutical composition comprising PE00642009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US90809807P true 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
PE00642009A1 true PE00642009A1 (en) 2009-03-02

Family

ID=39735057

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0005312008A PE00642009A1 (en) 2007-03-26 2008-03-24 ribonucleic acid double strand to inhibit expression of the human E6AP gene and pharmaceutical composition comprising

Country Status (11)

Country Link
US (1) US20100249052A1 (en)
EP (2) EP2137313A2 (en)
JP (1) JP2010522547A (en)
CN (1) CN101743311A (en)
AR (1) AR066397A1 (en)
AU (1) AU2008231816A1 (en)
CA (1) CA2681517A1 (en)
CL (1) CL2008000857A1 (en)
PE (1) PE00642009A1 (en)
TW (1) TW200902069A (en)
WO (1) WO2008116860A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999260A2 (en) 2006-03-24 2008-12-10 Novartis AG Dsrna compositions and methods for treating hpv infection
EP3210611A3 (en) 2010-03-12 2017-11-15 The Brigham and Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
BR112014008925A2 (en) 2011-10-11 2017-06-13 The Brigham And Women's Hospital Inc micro RNAs in neurodegenerative disorders
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
AU2014281031A1 (en) * 2013-06-17 2016-01-21 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
WO2014204728A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
KR20160030187A (en) * 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
RU2016128077A3 (en) * 2013-12-12 2018-12-06
EP3161159A4 (en) 2014-06-25 2018-02-07 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
US20180355016A1 (en) 2015-11-19 2018-12-13 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2019036375A1 (en) 2017-08-14 2019-02-21 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
JP3015383B2 (en) 1987-09-11 2000-03-06 ハワード・ヒユーズ・メデイカル・インスチチユート Fibroblasts and their use transduced
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
DE3851153D1 (en) 1987-12-11 1994-09-22 Whitehead Biomedical Inst Genetic modification of endothelial cells.
EP0732397A3 (en) 1988-02-05 1996-10-23 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5223168A (en) 1989-12-12 1993-06-29 Gary Holt Surface cleaner and treatment
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
AU667459B2 (en) 1990-08-03 1996-03-28 Sanofi Compounds and methods for inhibiting gene expression
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (en) 1990-09-20 1994-06-30
DK0568537T3 (en) 1990-10-31 1998-09-23 Whitehead Biomedical Inst Genetic modification of endothelial cells
EP0621944B1 (en) 1991-07-25 1997-03-05 The Whitaker Corporation Liquid level sensor
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
CA2122030C (en) 1991-10-24 1997-03-04 Muthiah Manoharan Derivatized oligonucleotides having improved uptake and other properties
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DE69407032T2 (en) 1993-03-31 1998-07-02 Sanofi Sa Oligonucleotides having amide linkages employ phosphoesterverkettungen
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5543417A (en) 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP3214177A3 (en) 1998-04-08 2017-11-22 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
AR020078A1 (en) 1998-05-26 2002-04-10 Syngenta Participations Ag Method for altering the expression of a target gene in a plant cell
MXPA01003643A (en) 1998-10-09 2003-07-21 Ingene Inc PRODUCTION OF ssDNA IN VIVO.
IL142490D0 (en) 1998-10-09 2002-03-10 Ingene Inc ENZYMATIC SYNTHESIS OF ssDNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for the inhibition of expression of a given gene
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
EP2348133B1 (en) * 2000-12-01 2014-07-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
CA2452653A1 (en) 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
US7923547B2 (en) * 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
DE10302421A1 (en) 2003-01-21 2004-07-29 Ribopharma Ag New double-stranded interfering RNA, useful for inhibiting hepatitis C virus, has one strand linked to a lipophilic group to improve activity and eliminate the need for transfection auxiliaries
JPWO2005116204A1 (en) * 2004-05-11 2008-06-19 株式会社アルファジェン Polynucleotide causing Rna interference, and the gene silencing method using the same
ES2381201T3 (en) * 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibitors subunit 2 of ribonucleotide reductase and uses thereof
EP1999260A2 (en) * 2006-03-24 2008-12-10 Novartis AG Dsrna compositions and methods for treating hpv infection
EP2527354A1 (en) * 2006-03-31 2012-11-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer

Also Published As

Publication number Publication date
AR066397A1 (en) 2009-08-19
JP2010522547A (en) 2010-07-08
WO2008116860A3 (en) 2009-03-12
TW200902069A (en) 2009-01-16
CN101743311A (en) 2010-06-16
EP2137313A2 (en) 2009-12-30
CL2008000857A1 (en) 2008-10-24
WO2008116860A2 (en) 2008-10-02
US20100249052A1 (en) 2010-09-30
EP2441837A1 (en) 2012-04-18
CA2681517A1 (en) 2008-10-02
AU2008231816A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
ES2613674T3 (en) Using the fungal organism Pythium oligandrum
RU2487716C2 (en) New structures of small interfering rna (sirna)
RU2501803C2 (en) Compositions and methods of modulation of expression of receptor of growth factor of fibroblasts 4 (fgfr4)
CL2014003475A1 (en) Crystalline form of obeticolico c acid; process preparation of form 1 of obeticolico acid from the crystalline form c; pharmaceutical composition comprising one, useful for the treatment or prevention of a cholestatic liver disease, alcoholic liver disease and cardiovascular diseases such as atherosclerosis, among other crystalline form of obeticolico acid.
CL2012003723A1 (en) Compounds derived from 2-quinolinyl-acid acetic acid; pharmaceutical composition; and use in the treatment of HIV and AIDS.
UY32085A (en) Kinase inhibitors and methods for their use
UA107174C2 (en) Saksahliptynu crystalline form and process for obtaining (options)
CR20110077A (en) Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol
ECSP099618A (en) fused ring compounds as partial agonists of PPAR-gamma
CY1117440T1 (en) Sytikta derivatives imidazolis AS INHIBITORS toy ido
UY33620A (en) Azido nucleoside analogs and nucleotide
CL2013001982A1 (en) Method to reduce glucose levels and treat metabolic disorders thereof; pharmaceutical composition comprising metformin and another antidiabetic agent or anti-obesity.
SV2010003673A (en) novel heterocyclic compounds and uses thereof
AR049723A1 (en) active for increased defense against pathogens in plants and methods for their detection substances
CL2012002489A1 (en) Compounds derived naphtho-imidazole silyl; pharmaceutical composition; and their use to prevent or treat an infection by Hepatitis C virus.
JP2003505422A5 (en)
BRPI0618094A2 (en) viral vaccines derived from cells with low residual DNA levels cell
EA200870401A1 (en) Compositions and methods to inhibit expression of the eg5 gene
RU2014124683A (en) MEANS FOR PHKi, compositions and methods of use for the treatment of diseases associated with transthyretin (TTR)
UY32062A (en) Beta secretase inhibitors
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
UY29086A1 (en) Novel pharmaceutical compositions for the treatment of hyperproliferative disorders.
BR112012010270A2 (en) mentisulfonilmetano (MSM) for the treatment of drug-resistant microorganisms
DK2358717T3 (en) Aminotetrahydropyraner as dipeptidyl peptidase-IV inhibitors tilbehandling or prevention of diabetes
CL2009002207A1 (en) Compounds derived from 3-hydroxy-5- (9H-purin-9-yl) tetrahydrofuran-2-yl, replication inhibitor of viral RNA-dependent RNA; pharmaceutical composition; use for the treatment of hepatitis c.

Legal Events

Date Code Title Description
FX Voluntary withdrawal